share_log

荃信生物-B:自願公告荃信生物於中國獲得QX013N針對慢性自發性蕁麻疹治療的新藥臨床試驗許可

QYUNS-B: VOLUNTARY ANNOUNCEMENTQYUNS OBTAINED IND CLEARANCE FOR QX013N FOR TREATMENT OFCHRONIC SPONTANEOUS URTICARIA IN CHINA

Hong Kong Stock Exchange ·  May 9 21:01

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.